Full-Time

Clinical Development Program Lead

Neuropsychiatry, Executive Director

Posted on 11/1/2025

Deadline 11/24/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$340.9k - $413.1k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Cambridge, MA, USA + 3 more

More locations: Summit, NJ, USA | Princeton, NJ, USA | San Diego, CA, USA

In Person

On-site roles; hybrid as per site protocol (Site-essential 100% onsite; Site-by-design may require at least 50% onsite)

Category
Medical, Clinical & Veterinary (3)
, ,
Requirements
  • MD (PhD or other high level degree optional)
  • The ideal candidate will be a clinical development leader; with greater than 10 years of extensive clinical trial, drug development, and regulatory experience, in addition to a strong scientific background
  • Management experience will be important since this individual will manage a group of professionals including MDs or PhDs or PharmDs with clinical research experience.
  • The successful candidate will understand early-stage drug development, extensive experience designing and conducting Phase I, II and Phase III clinical trials, and should have demonstrable success filing regulatory dossiers and prosecuting them through approval
  • Global experiences is a plus since this position has responsibility for strategy and clinical research in Neuropsychiatry in multiple geographies
  • Experience interacting with business development and licensing, particularly helping to evaluate the technical and franchise aspects for potential in-licensing opportunities that shape the Neuropsychiatry clinical development strategy
  • Travel Required: Domestic and International travel may be required.
Responsibilities
  • Strategy and Execution: Create and communicate a vision for designing, conducting and executing innovative clinical development plans
  • Strategy and Execution: This leader will supervise the development, monitoring, analysis and interpretation of clinical trials and will supervise and have accountability for the clinical components of regulatory filings
  • Strategy and Execution: Will contribute to overall strategy for specific disease / indications while ensuring a franchise overall portfolio view
  • Strategy and Execution: Provide strategic insights into the clinical development plans
  • Strategy and Execution: Lead search and evaluation activities on business development due diligence efforts, and advice to our strategic transactions group
  • Strategy and Execution: Key Member of Therapeutic Area Clinical Development Leadership Team and chairing forum as required
  • Strategy and Execution: Chair departmental Staff Meetings and represent governance meetings on an ad hoc basis
  • Strategy and Execution: Will build a franchise reputation that attracts innovators to bring their ideas to BMS
  • Drug Development Experience: Will create a Clinical Development strategy to develop programs beyond commercialization and launch and into lifecycle management
  • Leadership and Matrix Management: Lead and develop a group of Clinical Development professionals (team of up to 50 individuals both direct and indirect) whose therapeutic area focus is in a specific disease area / indication and will ensure scientific and technical excellence of clinical development programs and deliverables
  • Leadership and Matrix Management: This individual will recruit, develop and retain strong talent
  • Leadership and Matrix Management: Mentoring of talent/staff
  • Leadership and Matrix Management: Will establish an effective and ethical culture that encourages teamwork, peer review, promotes cooperation and provides a supportive culture
  • Leadership and Matrix Management: Will be responsible for developing a culture that values diversity of thought, supports coaching, fosters accountability and integrity, and supports process excellence and continuous improvement
  • Leadership and Matrix Management: Will be responsible for oversight of team budget and headcount
  • Stakeholder Engagement and Communication: Will work closely with colleagues in BMS Research, Development, Regulatory, Medical, Commercial and other key functional areas on a global basis; additionally should have an external focus and build relationships with thought leaders, physicians, and patient advocacy groups outside of BMS. Be recognized internally and externally as an expert in the field
  • Stakeholder Engagement and Communication: Partner and interact with colleagues from Research and Early Development who design and implement first in human through proof of concept trials and will assure a seamless transition into late stage development (Phase II-III trials.)
  • Governance Participation and Signature Authority: Governance participation ad hoc as designated
  • Governance Participation and Signature Authority: PRC Chair ad hoc as needed
  • Governance Participation and Signature Authority: Signature Authority for: CSRs, Health Authority Briefings, DMC Charters, Unblinding Requests, Health Authority Documents for Filings, and other clinical accountable documents delegated as needed

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE